Femoxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Femoxetine
Femoxetine.svg
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Biological half-life 7-27 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C20H25NO2
Molar mass 311.42 g/mol
3D model (Jmol)
  (verify)

Femoxetine (INN) (tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.

Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though).[1][2] Jorgen Buus-Lassen's name is on the pharmacology paper though.[3]

After Ferrosan's acquisition, femoxetine died from neglect.[4]

See also[edit]

References[edit]

  1. ^ U.S. Patent 3,912,743
  2. ^ U.S. Patent 4,007,196
  3. ^ Lassen, Jørgen Buus; Petersen, Erling; Kjellberg, Bengt; Olsson, Sven O. (1975). "Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics". European Journal of Pharmacology. 32 (1): 108–115. ISSN 0014-2999. doi:10.1016/0014-2999(75)90329-5. 
  4. ^ Healy, David (2004). Let them eat Prozac : the unhealthy relationship between the pharmaceutical industry and depression. New York, NY: New York Univ. Press. pp. 26–27. ISBN 9780814736692.